|Videos|June 26, 2023
Impact of Disease Staging on Prognosis and Treatment in SCLC
Panel experts review disease staging for limited and extensive stage small-cell lung cancer and discuss the impact of staging on treatment selection.
Advertisement
Episodes in this series
Advertisement
Related to this article
Sac-TMT plus pembrolizumab prolonged PFS over chemoimmunotherapy in PD-L1–negative nonsquamous lung cancer.
Adjuvant pembrolizumab continued to extend DFS in resected stage IB to IIIA NSCLC, though OS did not differ from placebo.
Longer DeLLphi-304 follow-up showed sustained OS, PFS, and response durability with tarlatamab in second-line small cell lung cancer.
Izalontamab brengitecan improved progression-free survival vs chemotherapy in EGFR-mutated lung cancer after a third-generation EGFR inhibitor.
Frontline savolitinib plus osimertinib improved progression-free survival vs osimertinib alone in EGFR-mutated, MET-overexpressing lung cancer.
In SAFFRON, the oral EGFR/MET inhibitor pairing extended survival over platinum/pemetrexed in MET-driven lung cancer that progressed on osimertinib.
Adding LK101 to tislelizumab-based first-line maintenance yielded early antitumor activity and signs of immune activation in advanced NSCLC.
Adding tarlatamab-dlle to durvalumab maintenance extended survival in extensive-stage small cell lung cancer in the phase 3 DeLLphi-305 trial.
Advertisement
Advertisement
Trending on OncLive
1
FDA Receives BLA for Etentamig in R/R Multiple Myeloma
2
Breaking Down Key Lung Cancer Data at ESMO 2026 With Drs Santos and Halmos
3
Petosemtamab Plus Pembrolizumab Hits Phase 3 OS, ORR Primary End Points in PD-L1+ R/M HNSCC
4
Sac-TMT Plus Pembrolizumab Improves PFS in PD-L1–Negative Nonsquamous NSCLC
5